Isopulegol Ameliorates Dyslipidemia by Modulating Adipokine Secretion in High Fat Diet / Streptozotocin Induced Diabetic Rats

Kalaivani Karunanithi, Sankaranarayanan Chandrasekaran *

Department of Biochemistry and Biotechnology, Annamalai University, Annamalainagar - 608002, Tamilnadu, India.

ABSTRACT

The present study investigates the effect of isopulegol on adipokine secretion and dyslipidemia in high fat diet and streptozotocin (HFD/STZ) induced diabetic rats. Animals were made diabetic by feeding HFD for 4 wks followed by single intraperitoneal injection of STZ (35mg/kg b.w) and 0.1M citrate buffer; pH 4.0. Diabetic rats showed increased levels of total cholesterol, triglycerides, free fatty acids, phospholipids, low density lipoprotein-C (LDL-C), very low density lipoprotein -C (VLDL-C) and decreased high density lipoprotein-C levels (HDL-C). Similarly, the activity of HMG-CoA reductase, was increased while lipoprotein lipase (LPL) and lecithin cholesterol acyl transferase (LCAT) activities were significantly decreased. Furthermore, the expression of sterol regulatory element binding protein-1C (SREBP-1C), adiponectin, peroxisome proliferator activated receptor gamma (PPARγ) were significantly down regulated, whereas leptin expression was upregulated in diabetic rats. Administration of isopulegol (100 mg/kg b.w) for 28 days significantly restored lipid levels in plasma and liver tissue of diabetic treated rats. From this we conclude that isopulegol exhibited significant antihyperlipidemic effect in HFD/STZ induced diabetic rats.

Keywords: Dyslipidemia, Diabetes mellitus, Adiponectin, Leptin, PPARγ, SREBP-1C

1. INTRODUCTION

Diabetic dyslipidemia in type 2 diabetes mellitus is characterised by a cluster of lipid and lipoprotein abnormalities which is an important risk factor for coronary artery disease and stroke. High fat diet and oxidative damage contributes to the development of dyslipidemia and impairs insulin signaling in diabetes mellitus [1]. Lack of responsiveness and an inability to control hyperlipidemia are the drawbacks associated with the long term use of the currently available antidiabetic drugs Controlling dyslipidemia is of prime importance in preventing cardiovascular risk in diabetes mellitus. The rationale use of phytochemicals offers hope for a more effective drug in the management of diabetes mellitus.

Isopulegol a naturally occurring monoterpenoid is widely distributed in grape fruit, mint, rosemary oil and possesses numerous pharmacological properties [2]. Recently, we reported that isopulegol regulated the activities of carbohydrate metabolic enzymes and improved insulin secretion in high fat diet (HFD)/streptozotocin (STZ) induced diabetic rats [3]. In this context the present study was designed to investigate the potential role of isopulegol on dyslipidemia, and on adipokine levels in HFD/STZ induced diabetic rats.

2. MATERIALS AND METHODS:

2.1. Chemicals and drugs

Isopulegol and STZ were purchased from Sigma Aldrich Pvt. Ltd., (St.Louis, MO,USA). Diagnostic kits for cholesterol and triglycerides were purchased from Agappe diagnostics Ltd, Kerala, India. All other chemicals used in this study were of analytical grade and obtained from SD fine and HIMEDIA, India.

2.2. Ethical statement for animal experimentation

Thirty adult male wistar rats with body weight ranging from 180 to 200 g were purchased from National Centre for Laboratory Animal Science, Bangalore. They were housed in well-ventilated cages (temperature 23 ± 2 °C, humidity 65-70% and 12 h light/dark cycle), fed on pellet diet and water ad libitum. Studies were carried out in accordance with
Indian National Law on Animal Care and Use and were approved by the Institutional ethical committee (Proposal No.1000) of Rajah Muthiah Medical College and Hospital, Annamalai University, India.

2.3 Development of type 2 diabetes mellitus
Rats divided into five groups with six in each group were placed under normal pellet diet and water for a week prior to dietary manipulation. Experimental animals in three groups were fed with a HFD (40%) for 4 weeks. This was followed by a single intraperitoneal injection of freshly prepared STZ (35 mg/kg b.w) dissolved in 0.1M citrate buffer (pH 4.5). After one week, fasting blood glucose levels were determined and rats with glucose levels > 250 mg/dl were considered as diabetic and used in this study.

2.4 Experimental design
Animals were grouped and treated as follows.
- **Group I**: Control rats fed with normal pellet diet
- **Group II**: Control rats fed with normal pellet diet and administered p.o with an aqueous solution of isopulegol (200 mg/kg b.w)
- **Group III**: Diabetic rats fed with high fat diet
- **Group IV**: Diabetic rats administered p.o with an aqueous solution of isopulegol (100 mg/kg b.w)
- **Group V**: Diabetic rats administered p.o with an aqueous solution of metformin (25 mg/kg b.w)

2.5 Extraction and assay of lipids
Lipid extraction from tissues were carried out by the method of Folch et al [4]. By adopting suitable methods the levels of TC [5], HDL-C [6], LDL-C & VLDL-C [7], TG [8], FFA [9], PL [10], LPL and LCAT activity [11, 12] were measured.

2.6 Western blotting analysis
The expression pattern of adiponectin and leptin were analysed in the adipose tissue [13].

2.7 Histological examination
Haematoxylin and eosin staining of adipose tissue was performed as described by Hine [14].

2.8 Quantitative real time -PCR (q RT-PCR)
Total RNA was extracted using TRizol reagent (Invitrogen Bioservices India Pvt. Ltd) according to the manufacturer’s instructions. The reverse transcription reaction was conducted using miScript Reverse Transcription Kit (Genei, India). Real-time PCR was conducted on the PCR System with SYBR Premix Ex Taq (Bangalore, India)

2.9 Statistical analysis
All data were expressed as mean ± SD of number of experiments (n = 5). The statistical significance was evaluated by one-way analysis of variance (ANOVA) using SPSS version 20 (SPSS, Cary, NC, USA) and the individual comparison were obtained by Duncan’s multiple range test (DMRT).

3. RESULTS
3.1 Influence of isopulegol on circulating lipids
Table 1 shows the levels of TC, TGs, PLs, FFAs in plasma of control and experimental rats. Diabetic rats showed significantly elevated levels of TC, TGs, FFAs and PL levels when compared with normal rats. Oral administration of isopulegol (100 mg/kg b.w) for 28 days to diabetic rats significantly reduced the levels of above lipids when compared to diabetic rats. These findings are comparable with metformin treated diabetic rats.
Table 1: Effect of isopulegol on the levels of TC, TGs, FFAs and PLs in the plasma of normal and experimental rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>TC (mg/dl)</th>
<th>TGs (mg/dl)</th>
<th>FFAs (mg/dl)</th>
<th>PLs (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>95.21 ± 7.25</td>
<td>80.61 ± 6.13</td>
<td>63.31 ± 4.82</td>
<td>85.21 ± 6.49</td>
</tr>
<tr>
<td>Normal + isopulegol (200mg/kg b.w)</td>
<td>96.04 ± 7.35</td>
<td>85.24 ± 6.52</td>
<td>62.03 ± 4.74</td>
<td>76.34 ± 5.84</td>
</tr>
<tr>
<td>Diabetic (HFD/STZ)</td>
<td>167.28 ± 12.80</td>
<td>154.37 ± 11.81</td>
<td>130.16 ± 9.96</td>
<td>150.27 ± 11.50</td>
</tr>
<tr>
<td>Diabetic + isopulegol (100mg/kg b.w)</td>
<td>120.36 ± 9.21</td>
<td>110.25 ± 8.44</td>
<td>80.64 ± 6.17</td>
<td>108.25 ± 8.28</td>
</tr>
<tr>
<td>Diabetic + metformin (25 mg/kg b.w)</td>
<td>108.52 ± 8.26</td>
<td>95.51 ± 7.27</td>
<td>72.81 ± 5.54</td>
<td>97.61 ± 7.43</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD for six rats. Values not sharing a common superscript (a-d) differ significantly at P<0.05 (DMRT)

3.2. Effect of isopulegol on lipid profile in hepatic tissue

The levels of TC, FFA, PL and TG in hepatic tissue of control and experimental rats were shown in Table 2. Diabetic rats exhibited a significant increase in the lipid content compared to normal rats. Administration of isopulegol to diabetic rats significantly reversed the lipid content in hepatic tissue to near normal.

Table 2: Effect of isopulegol on the levels of TC, TGs, FFAs and PLs in the hepatic tissue of normal and experimental rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>TC (mg/dl)</th>
<th>TGs (mg/dl)</th>
<th>FFAs (mg/dl)</th>
<th>PLs (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>5.60 ± 0.42</td>
<td>4.05 ± 0.30</td>
<td>18.05 ± 1.37</td>
<td>21.50 ± 1.63</td>
</tr>
<tr>
<td>Normal + isopulegol (200mg/kg b.w)</td>
<td>5.30 ± 0.40</td>
<td>4.10 ± 0.31</td>
<td>17.04 ± 1.30</td>
<td>20.62 ± 1.57</td>
</tr>
<tr>
<td>Diabetic (HFD/STZ)</td>
<td>9.80 ± 0.74</td>
<td>7.90 ± 0.60</td>
<td>30.91 ± 2.36</td>
<td>38.82 ± 2.96</td>
</tr>
<tr>
<td>Diabetic + isopulegol (100mg/kg b.w)</td>
<td>7.70 ± 0.58</td>
<td>6.70 ± 0.51</td>
<td>22.81 ± 1.74</td>
<td>30.71 ± 2.35</td>
</tr>
<tr>
<td>Diabetic + metformin (25 mg/kg b.w)</td>
<td>6.90 ± 0.52</td>
<td>5.80 ± 0.43</td>
<td>20.70 ± 1.57</td>
<td>26.80 ± 2.03</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD for six rats. Values not sharing a common superscript (a-d) differ significantly at P<0.05 (DMRT)

3.3. Effect of isopulegol on lipoprotein cholesterol in plasma

Table 3 depicts the levels of lipoproteins cholesterol (HDL-C, LDL-C and VLDL-C) in the plasma of normal and experimental rats. The level of HDL-C was decreased whereas the levels of LDL-C and VLDL-C were significantly increased in diabetic rats when compared to normal control. Administration of isopulegol (100mg/kg b.w) decreased the levels of LDL-C, VLDL-C and significantly improved HDL-C levels in diabetic treated rats. The results are comparable with metformin (25mg/kg b.w) treated groups.

Table 3: Effect of isopulegol on the levels of HDL-C, LDL-C, VLDL-C in the plasma of normal and experimental rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>HDL-C (mg/dl)</th>
<th>LDL-C (mg/dl)</th>
<th>VLDL-C (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>48.00 ± 3.65</td>
<td>38.00 ± 2.89</td>
<td>18.20 ± 1.38</td>
</tr>
<tr>
<td>Normal + isopulegol (200mg/kg b.w)</td>
<td>47.02 ± 3.59</td>
<td>36.71 ± 2.81</td>
<td>19.11 ± 1.46</td>
</tr>
<tr>
<td>Diabetic (HFD/STZ)</td>
<td>24.61 ± 1.88</td>
<td>90.24 ± 6.91</td>
<td>32.51 ± 2.48</td>
</tr>
<tr>
<td>Diabetic + isopulegol (100mg/kg b.w)</td>
<td>34.61 ± 2.64</td>
<td>50.92 ± 3.89</td>
<td>25.61 ± 1.95</td>
</tr>
<tr>
<td>Diabetic + metformin (25 mg/kg b.w)</td>
<td>40.50 ± 3.08</td>
<td>43.70 ± 3.32</td>
<td>21.80 ± 1.65</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD for six rats. Values not sharing a common superscript (a-d) differ significantly at P<0.05 (DMRT)

3.4. Role of isopulegol on the activites of LPL and LCAT in plasma

The activites of LCAT and LPL in plasma of normal control and experimental rats were shown in Table 4. Decreased activites of LCAT and LPL were observed in the plasma of diabetic rats as compared to normal rats. Administration of isopulegol (100 mg/kg b.w) and metformin (25mg/kg b.w) to diabetic rats significantly increased the activites of LCAT and LPL towards near normal.

Table 4: Effect of isopulegol on the activites of LPL and LCAT in plasma of normal and experimental rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>LPL (units/ml)</th>
<th>LCAT (units/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>40.50 ± 3.08</td>
<td>21.80 ± 1.65</td>
</tr>
<tr>
<td>Normal + isopulegol (200mg/kg b.w)</td>
<td>43.70 ± 3.32</td>
<td>25.61 ± 1.95</td>
</tr>
<tr>
<td>Diabetic (HFD/STZ)</td>
<td>50.92 ± 3.89</td>
<td>23.51 ± 2.48</td>
</tr>
<tr>
<td>Diabetic + isopulegol (100mg/kg b.w)</td>
<td>34.61 ± 2.64</td>
<td>19.11 ± 1.46</td>
</tr>
<tr>
<td>Diabetic + metformin (25 mg/kg b.w)</td>
<td>36.71 ± 2.81</td>
<td>19.02 ± 1.38</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD for six rats. Values not sharing a common superscript (a-d) differ significantly at P<0.05 (DMRT)
Table 4: Effect of isopulegol on the activities of plasma LPL and LCAT of normal and experimental rats

<table>
<thead>
<tr>
<th>Groups</th>
<th>LPL (μ moles of glycerol liberated/h/l)</th>
<th>LCAT (μ moles of cholesterol esterified/h/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>8.20 ± 0.62&lt;sup&gt;a&lt;/sup&gt;</td>
<td>86.21 ± 6.56&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Normal+ isopulegol (200 mg/kg b.w)</td>
<td>7.30 ± 0.55&lt;sup&gt;a&lt;/sup&gt;</td>
<td>87.39 ± 6.68&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic (HFD/STZ)</td>
<td>4.50 ± 0.34&lt;sup&gt;b&lt;/sup&gt;</td>
<td>50.82 ± 3.88&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic+ isopulegol (100 mg/kg b.w)</td>
<td>5.70 ± 0.43&lt;sup&gt;c&lt;/sup&gt;</td>
<td>65.73 ± 5.03&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic + metformin (25 mg/kg b.w)</td>
<td>6.85 ± 0.52&lt;sup&gt;d&lt;/sup&gt;</td>
<td>75.91 ± 5.77&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Values are expressed as mean ± SD for six rats. Values not sharing a common superscript (a-d) differ significantly at P<0.05 (DMRT).

3.5 Effect of isopulegol on the activity of HMG-CoA reductase in hepatic tissue

Figure 1 shows the activity of HMG-CoA reductase in control and experimental animals. The activity of HMG-CoA reductase was increased significantly in hepatic tissue of diabetic rats. Oral administration of Isopulegol as well as metformin to diabetic rats significantly decreased the activity of HMG-CoA reductase in these tissue when compared to diabetic control rats.

Figure 1: Effect of isopulegol on the activity of HMG-CoA reductase in hepatic tissue of control and experimental rats

Values are expressed as mean ± SD for six rats. Values not sharing a common superscript (a-d) differ significantly at P<0.05 (DMRT).

3.6 Role of isopulegol on the expression of adiponectin and leptin

Figures 2 and 3 depicts the protein expression pattern of adiponectin and leptin in the adipose tissue of experimental rats. Significant downregulation of adiponectin with an upregulation of leptin expression was observed in diabetic control rats. Isopulegol (100 mg/kg b.w) treated diabetic rats significantly restored the protein expression pattern in the adipose tissue.
Figure 2: Effect of isopulegol on adiponectin protein expression in the adipose tissue of normal and experimental rats

A. Western blot analysis

Lane 1: Normal; Lane 2: Normal+ isopulegol (200mg/kg b.w); Lane 3: Diabetic (HFD/STZ); Lane 4: Diabetic+ isopulegol (100mg/kg b.w); Lane 5: Diabetic + metformin (25 mg/kg b.w)

B. Band intensity scanned by densitometer

Histograms depict quantization of three independent experiments (mean ± S.D), with data normalized by defining the control group with adiponectin, as 1 unit. Values are not sharing a common superscript differ significantly at p<0.05 (DMRT)
Figure 3: Effect of isopulegol on leptin protein expression in the adipose tissue of normal and experimental rats

A. Western blot analysis

Lane 1: Normal; Lane 2: Normal+ isopulegol (200mg/kg b.w); Lane 3: Diabetic (HFD/STZ); Lane 4: Diabetic+ isopulegol (100mg/kg b.w); Lane 5: Diabetic + metformin (25 mg/kg b.w)

B. Band intensity scanned by densitometer

Histograms depicts quantization of three independent experiments (mean ± S.D), with data normalized by defining the control group with adiponectin, as 1 unit. Values are not sharing a common superscript differ significantly at p<0.05 (DMRT)

3.7. Effect of isopulegol on mRNA expression of PPARγ and SREBP-1C in diabetic rats

The effect of isopulegol on the mRNA expression of PPARγ and SREBP-1C in the adipose tissue of diabetic rats are shown in (Figures 4 - 6). The levels of PPARγ mRNA expression was significantly down regulated whereas SREBP-1C mRNA expression were significantly up regulated in diabetic rats compared to control rats. Treatment with isopulegol (100mg/kg b.w) significantly modulated PPARγ and SREBP-1C mRNA expression to near normal in treated diabetic rats compared to metformin treated rats.
Figure 4: Analysis of PPARγ expression by qRT-PCR in adipose tissue of experimental rats

q-RT-PCR analysis graph. b) PPARγ mRNA expression by q-RT-PCR in adipose tissue. Experiments were carried out in triplicates and data expressed are mean ± SD of 6 rats from each group. The Ct values of the test gene of each group were standardized using Ct value of GAPDH of the same group. Values are expressed relative to those control rats that were arbitrarily assigned a value of 1.0.

Figure 5: Analysis of SREBP-1C expression by qRT-PCR in adipose tissue of experimental rats

q-RT-PCR analysis graph. b) SREBP-1C mRNA expression by q-RT-PCR in adipose tissue. Experiments were carried out in triplicates and data expressed are mean ± SD of 6 rats from each group. The Ct values of the test gene of each group were
standardized using Ct value of GAPDH of the same group. Values are expressed relative to those control rats that were arbitrarily assigned a value of 1.0.

Figure 6: Analysis of SREBP-1C expression by qRT-PCR in the liver of experimental rats

![Graph showing analysis of SREBP-1C expression by qRT-PCR](image)

qRT-PCR analysis graph. b) SREBP1-C mRNA expression by qRT-PCR in liver tissue. Experiments were carried out in triplicates and data expressed are mean ± SD of 6 rats from each group. The Ct values of the test gene of each group were standardized using Ct value of GAPDH of the same group. Values are expressed relative to those control rats that were arbitrarily assigned a value of 1.0.

3.8. Histology

Histological observations of haematoxylin-eosin-stained adipose tissue of control and treated rats are shown in (Figure 7). Diabetic rats showed swollen arrangement of cells in the epididymal adipose tissue. Oral administration of isopulegol (100mg/kg b.w) restored the architecture of adipose tissue to near normal.
Figure 7: Histopathological changes in adipose tissue of normal and experimental rats

4. DISCUSSION

Increasing availability of energy dense food and sedentary lifestyle have led to a worldwide epidemic of type 2 diabetes mellitus. Dyslipidemia is a common biochemical feature in T2DM and is one of the major risk factors for cardiovascular and peripheral vascular disease (CVD) [15]. Insulin deficiency/resistance contributes to quantitative and qualitative lipid abnormalities with a shift towards atherogenic lipid profile that result in microvascular and macrovascular disorders.

Free fatty acids are products of fat metabolism in adipose tissues and it is the main circulating lipid fuel in the post-absorptive state. The mobilization of free fatty acids from stored TG occurs sequentially and requires the activation of hormone sensitive lipase (HSL), a key enzyme considered as crucial in regulating lipolysis in fat cells [16]. This enzyme is under tight hormonal and neuronal control and it has been found that variations in HSL expression modulate lipolysis in adipose tissue. In the diabetic state, insulin deficiency causes activation of HSL that results in hydrolysis of TG with concomitant release of large amounts of free fatty acids in circulation.

Hypertriglyceridemia is a common finding in diabetic patients and is responsible for vascular complications. Lipid accumulation in hepatic tissue is mediated through a variety of derangements in metabolic and regulatory processes leading to hypercholesterolemia and hypertriglyceridemia [17]. In the diabetic state, insulin deficiency increases mobilization of fatty acids from adipose tissue which are channeled to liver and esterified resulting in hypertriglyceridemia [18].

Furthermore, lipoprotein lipase (LPL) catalyses the hydrolysis of the triglyceride component of chylomicrons, VLDL and provides non-esterified fatty acids and 2-
monacylglycerol for tissue utilisation. In diabetes mellitus, due to insulin deficiency the expression and activity of LPL is decreased resulting in impaired metabolism of TG rich lipoproteins leading to hypertriglyceridemia. We observed an increase in FFA, TG and LPL activity in HFD/STZ diabetic rats.

Sterol regulatory element (SREBPs) transcription factor regulate the expression of lipogenic genes, such as fatty acid synthase and acetyl-CoA carboxylase, involved in lipid biosynthesis and uptake [19]. Studies have shown that increased expression of SREBP-1C accelerate TG accumulation in diabetic rats [20]. We observed an upregulation in the mRNA expression of SREBP-1C in the hepatic and adipose tissue of diabetic rats.

Cholesterol homeostasis is an important metabolic process which reflects a balance between numbers of complex/interactive processes. The biosynthesis of cholesterol is regulated by the rate-limiting enzyme HMG-CoA reductase, which catalyzes production of mevalonic acid. Increased activity of HMG-CoA reductase results in the excessive production and accumulation of cholesterol leading to the formation of foam cells, a pre-requisite step in the development of atherosclerosis [21]. Insulin deficiency is associated with decreased HMG CoA/mevalonate ratio indicating increased enzyme activity. Numerous studies have highlighted that the activity of HMG-CoA reductase is increased in diabetic rats [22].

Phospholipids are vital components of bio membranes that play an important role in the maintenance of cellular integrity, micro viscosity and survival. An elevation of FFA and cholesterol in diabetic rats, promote the synthesis of PLs [23]. PLs are susceptible substrates for oxygen and hydroxyl free radicals generated in diabetic state. In DM, chronic hyperglycemia alters fatty acids, lipids and decreases the activities of membrane-bound enzymes [24]. We observed an increase in cholesterol, phospholipids and HMG CoA reductase activity in plasma and liver tissue of diabetic rats.

In the present study, treatment with isopulegol (100mg/kg b.w) for 28 days was sufficient to produce a significant decrease in the levels of FFA, TC, TG, PL and in the mRNA expression of SREBP-1C in diabetic treated rats. Similarly, the observed increase in HMG-CoA reductase and a decrease in LPL activity were restored to near normal in isopulegol treated diabetic rats. These results indicate that isopulegol has significant lipid lowering effect in diabetic treated rats. Our findings are in line with wang et al who reported that Inonotus obliquus polysaccharides normalized lipid profile in streptozocin diabetic rats [25].

In diabetic state, alterations in lipoprotein patterns are accompanied by changes in variety of biochemical processes. The transport of TG from liver to extrahepatic tissues for utilization and storage is achieved by VLDL [26]. Increased free fatty acid flux from lipolysis under insulin resistant conditions results in excessive production of VLDLs in the liver. These particles are synthesized in the liver and contain apo B-100 as their apolipoprotein component. Insulin deficiency increases the flux of metabolites to liver leading to overproduction of VLDL and also enhances its secretion through regulating the turnover apoB100 [27]. This process is severely impaired in diabetes mellitus resulting in increased VLDL-C in circulation.

LDL cholesterol (LDL-C) is central importance in evaluating the effects of lipid modifying therapies. The atherogenic properties of LDL particles are related to their ability to penetrate the arterial wall and make them susceptible to oxidation. Increased LDL-C may arise on glycosylation of the lysyl residue of apoprotein B as well as from decreasing affinity for the LDL receptor. These modifications result in decreased clearance of LDL particles by LDL-receptor (LDL-R) and contribute to their elevated plasma levels [28]. A positive correlation exists between the incidence of coronary atherosclerosis and the oxidative modification of LDL particles.

HDL promotes the reverse transport of cholesterol from peripheral tissues to liver with the help of ABCA1 transporter protein. The anti-atherogenic effect of HDL is due to its antioxidant/anti-inflammatory function, which is of great significance in DM. The antioxidant effect is related to the presence of HDL-linked proteins (apo-A1, lecithin: cholesterol acyltransferase (LCAT), platelet-activating factor (PAF, acetyl hydrolase) and paraoxonase (PON). HDL also acts as a repository of apolipoproteins C and E and governs the metabolism of chylomicrons and VLDL. Apo A1, the major apo protein of HDL-C is glycated in uncontrolled diabetes and results in increased permission of HDL particles from circulation [29]. LCAT a key enzyme in HDL-C metabolism facilitates the transfer of a fatty acid from position 2 of lecithin to cholesterol to form cholesteryl esters. This allows the transfer of cholesteryl ester to the core of HDL particle rendering the continuous uptake of free cholesterol by HDL. A decrease in LCAT activity severely impairs HDL-C synthesis and TGs metabolism in diabetic rats [30].

We observed a significant increase in VLDL-C and LDL-C levels with a decrease in HDL-C level in the plasma of diabetic rats. A decreased activity of LCAT was observed in plasma of diabetic rats. Treatment with isopulegol (100mg/kg b.w) improved lipoprotein cholesterol levels and LCAT activity in diabetic treated rats. The hypolipidemic effect of isopulegol is attributed to a significant reduction in blood glucose concentration via enhanced insulin secretion. This enhancement in insulin increases utilization of glucose and decreases the mobilization of FFA from fat depots. Our results are consistent with Antony et al (2016) who reported that myoinositol improved lipoprotein cholesterol levels and LCAT activity in HFD/STZ diabetic rats.

Adiponectin, improves insulin sensitivity and regulates energy homeostasis. It has been shown that adiponectin activates AMP-activated protein kinase (AMPK) and reduces the expression of gluconeogenic genes and enhances insulin sensitivity both in skeletal muscle and liver [31]. It is suggested that adiponectin plays an important role in lipid metabolism by stimulating fatty acid oxidation in liver and muscle, decreases plasma triglycerides and enhances glucose metabolism. High-fat diet and STZ induced diabetes was accompanied by a reduction in plasma adiponectin levels [32].

Leptin, decreases food intake, body weight and modulates sugars and fat metabolism. It targets pancreatic β-cell, modulates insulin expression and secretion[33]. It also influences lipid metabolism by preventing TG accumulation in peripheral tissues. It has been found out that leptin stimulates fatty acid oxidation through AMP-activated protein kinase (AMPK) and subsequently inhibits acetyl-CoA carboxylase (ACC) activity in the skeletal muscle [34]. Increased circulating levels of leptin have been found to be associated with obesity and in chronic consumption of high-fat diet. Studies have reported that circulating levels of leptin and leptin are increased on high fat feeding in C57BL/6 mice [35].

Our study revealed a significant down regulation in the expression of PPARY, adiponectin and an upregulation of leptin expression in the adipose tissue of diabetic rats. Histopathological studies of revealed hypertrophy and
infiltration of macrophages in adipose tissue suggesting profound dysfunction in HFD/STZ diabetic rats. Administration of isopulegol and metformin to diabetic rats markedly restored changes in the expression levels of PPARγ, adiponectin and leptin in adipose tissue. The possible mechanism of isopulegol in the improvement of adipocytokines may be due to the activation of PPARγ in the adipose tissue. Our findings are in agreement with Hosni et al. that cinnamaldehyde effectively improved insulin secretion and sensitivity by up regulation of PPARγ gene expression and diminishing the proinflammatory cytokines in diabetic rats [36].

5. CONCLUSION

From this we conclude that administration of isopulegol effectively regulated adipokine expression, restored the levels of lipids and lipoprotein cholesterol by regulating the activities of key enzymes and ameliorated dyslipidemia in diabetic rats. In addition, histopathological studies revealed a protective effect of isopulegol. Further studies are warranted to unravel the molecular action of isopulegol in controlling dyslipidemia in diabetes mellitus.

6. ACKNOWLEDGEMENT

The authors gratefully thank UGC and DST, New Delhi for their financial support to the department.

7. CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

8. REFERENCES
